Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: Results from a randomized, controlled study

Menopause

Volumn 15, Issue 6, 2008, Pages 1065-1069

  Davis, Susan R ^a,d   Stuckey, Bronwyn G A ^b   Norman, Robert J ^c   Papalia, Mary Anne ^a   Drillich, Ann ^a   Bell, Robin J ^a  

^a ALFRED HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF ADELAIDE   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Estrogen; Insulin resistance; Postmenopausal women

Indexed keywords

ESTRADIOL; ESTRADIOL PLUS NORETHISTERONE; ESTRADIOL PLUS NORETHISTERONE ACETATE; GLUCOSE; INSULIN; NORETHISTERONE; PLACEBO; S 21405; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HORMONAL THERAPY; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; NORMAL HUMAN; POSTMENOPAUSE; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; CARDIOVASCULAR DISEASE; ESTROGEN THERAPY; GLUCOSE TOLERANCE TEST; INTRANASAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; CARDIOVASCULAR DISEASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; INSULIN RESISTANCE; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; MIDDLE AGED; NORETHINDRONE; POSTMENOPAUSE;

EID: 63349111764     PISSN: 10723714     EISSN: None     Source Type: Journal    
DOI: 10.1097/gme.0b013e318174f16e     Document Type: Article

References (31)

1. Public Health Group. Victorian Burden of Disease Study. Mortality and Morbidity in 2001. Available at: http://www.health.vic.gov.au/health-status/ bodvic/bod-current.htm. Accessed June 28, 2007.
2. Lieberman EH, Gerhard MD, Uehata A, et al. Estrogen improves endothelium-dependent, flow mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936-941.
3. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 1994;73:951-957.
4. Rossouw J, Anderson G, Prentice R, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-333.
5. Baxter RC. Circulating binding proteins for the insulinlike growth factors. Trends Endocrinol Metab 1993;4:91-96.
6. Boquist S, Ruotolo G, Skoglund-Andersson C, et al. Correlation of serum IGF-I and IGFBP-1 and -3 to cardiovascular risk indicators and early carotid atherosclerosis in healthy middle-aged men. Clin Endocrinol (Oxf) 2007;68:51-58.
7. Colao A, Spiezia S, Di Somma C, et al. Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age. J Endocrinol Invest 2005;28:440-448.
8. Johnsen SP, Hundborg HH, Sorensen HT, et al. Insulin-like growth factor (IGF) I-II, and IGF binding protein-3 and risk of ischemic stroke. J Clin Endocrinol Metab 2005;90:5937-5941.
9. Watanabe T, Itokawa M, Nakagawa Y, Iguchi T, Katagiri T. Increased levels of insulin-like growth factor binding protein-3 in hypertensive patients with carotid atherosclerosis. Am J Hypertens 2003;16:754-760.
10. Weissberger AJ, Ho KK, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insulin-like growth factor I, and GH-binding protein in postmenopausal women. J Clin Endocrinol Metab 1991;72:374-381.
11. Sonnet E, Lacut K, Roudaut N, Mottier D, Kerlan V, Oger E. Effects of the route of oestrogen administration on IGF-1 and IGFBP-3 in healthy postmenopausal women: results from a randomized placebo-controlled study. Clin Endocrinol (Oxf) 2007;66:626-631.
12. Toth MJ, Sites CK, Eltabbakh GH, Poehlman ET. Effect of menopausal status on insulin-stimulated glucose disposal: comparison of middle-aged premenopausal and early postmenopausal women. Diabetes Care 2000;23:801-806.
13. Kalish G, Barrett-Connor E, Laughlin G, Gulanski B. Association of endogenous sex hormones and insulin resistance among postmenopausal women: results from the Postmenopausal Estrogen/Progestin Intervention Trial. J Clin Endocrinol Metab 2003;88:1646-1652.
14. Seaquist ER. Does WHI tell us how to prevent diabetes? Diabetologia 2004;47:1133-1134.
15. Saucedo R, Basurto L, Zarate A, Martinez C, Hernandez M, Galvan R. Effect of estrogen therapy on insulin resistance and plasminogen activator inhibitor type 1 concentrations in postmenopausal women. Gynecol Obstet Invest 2007;64:61-64.
16. Davis SR, Davison SL, Wilson S, Shepherd J, Lawton B. Intranasal versus transdermal matrix oestrogen replacement in Australasian women. Maturitas 2005;51:163-171.
17. Devissaguet JP, Brion N, Lhote O, Deloffre P. Pulsed estrogen therapy: pharmacokinetics of intranasal 17-β-estradiol (S21400) in postmenopausal women and comparison with oral and transdermal formulations. Eur J Drug Metab Pharmacokinet 1999;24:265-271.
18. Hemelaar M, Kenemans P, de Bie L, van de Weijer PH, van der Mooren MJ. Intranasal continuous combined 17 β-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women. Fertil Steril 2006;85:979-988.
19. Diamanti-Kandarakis E, Kouli C, Alexandraki K, Spina G. Failure of mathematical indices to accurately assess insulin resistance in lean, overweight, or obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2004;89:1273-1276.
20. Mattson LA, Christiansen C, Colau JC, et al. Clinical equivalence of intranasal and oral 17β estradiol for postmenopausal symptoms. Am J Obstet Gynecol 2000;182:545-552.
21. Helle SI, Omsjo IH, Hughes SC, et al. Effects of oral and transdermal oestrogen replacement therapy on plasma levels of insulin-like growth factors and IGF binding proteins 1 and 3: a cross-over study. Clin Endocrinol (Oxf) 1996;45:727-732.
22. Cano A, Castelo-Branco C, Tarin JJ. Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels. Fertil Steril 1999;71:261-267.
23. Garnero P, Tsouderos Y, Marton I, Pelissier C, Varin C, Delmas PD. Effects of intranasal 17β-estradiol on bone turnover and serum insulin-like growth factor I in postmenopausal women. J Clin Endocrinol Metab 1999;84:2390-2397.
24. Doren M, Azzawi FA, Donnez J, Van der Mooren MJ, Villero J, Gompel A. Therapeutic value and long-term safety of pulsed estrogen therapy. Maturitas 2001;38(Suppl 1):S23-S30.
25. Lievertz RW. Pharmacology and pharmacokinetics of estrogens. Am J Obstet Gynecol 1987;156:1289-1293.
26. Leung KC, Johannsson G, Leong GM, Ho KK. Estrogen regulation of growth hormone action. Endocr Rev 2004;25:693-721.
27. Lissett CA, Shalet SM. The impact of dose and route of estrogen administration on the somatotropic axis in normal women. J Clin Endocrinol Metab 2003;88:4668-4672.
28. Friend KE, Hartman ML, Pezzoli SS, Clasey JL, Thorner MO. Both oral and transdermal estrogen increase growth hormone release in postmenopausal women - a clinical research center study. J Clin Endocrinol Metab 1996;81:2250-2256.
29. Nugent AG, Leung KC, Sullivan D, Reutens AT, Ho KK. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women. Clin Endocrinol (Oxf) 2003;59:690-698.
30. O'Sullivan AJ, Ho K. A comparison of the effects of oral and transdermal estrogen replacement on insulin sensitivity in postmenopausal women. J Clin Endocrinol Metab 1995;80:1783-1788.
31. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-419.